Paloma Partners Management Co increased its holdings in STERIS (NYSE:STE) by 190.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,493 shares of the medical equipment provider’s stock after purchasing an additional 10,809 shares during the period. Paloma Partners Management Co’s holdings in STERIS were worth $1,442,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the stock. Benjamin F. Edwards & Company Inc. boosted its holdings in STERIS by 5.9% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 9,817 shares of the medical equipment provider’s stock worth $859,000 after purchasing an additional 547 shares in the last quarter. Comerica Bank boosted its holdings in STERIS by 0.9% during the fourth quarter. Comerica Bank now owns 68,219 shares of the medical equipment provider’s stock valued at $6,255,000 after acquiring an additional 628 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in STERIS by 6.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 9,810 shares of the medical equipment provider’s stock valued at $858,000 after acquiring an additional 630 shares during the period. OppenheimerFunds Inc. boosted its holdings in STERIS by 9.2% during the fourth quarter. OppenheimerFunds Inc. now owns 8,352 shares of the medical equipment provider’s stock valued at $731,000 after acquiring an additional 703 shares during the period. Finally, Swiss National Bank boosted its holdings in STERIS by 0.6% during the third quarter. Swiss National Bank now owns 142,255 shares of the medical equipment provider’s stock valued at $12,575,000 after acquiring an additional 800 shares during the period. Hedge funds and other institutional investors own 89.40% of the company’s stock.
In related news, VP Karen L. Burton sold 1,500 shares of the stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $85.59, for a total value of $128,385.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $95.50, for a total transaction of $955,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,415 shares of company stock valued at $7,178,536. 2.55% of the stock is owned by corporate insiders.
Shares of NYSE STE traded down $1.95 during mid-day trading on Friday, hitting $92.25. The company had a trading volume of 293,603 shares, compared to its average volume of 346,333. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.22 and a current ratio of 2.82. STERIS has a 12 month low of $69.12 and a 12 month high of $96.43. The stock has a market cap of $7,827.23, a PE ratio of 24.53 and a beta of 1.12.
STERIS (NYSE:STE) last released its earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.05. STERIS had a net margin of 9.42% and a return on equity of 11.57%. The business had revenue of $661.90 million during the quarter, compared to analysts’ expectations of $663.17 million. During the same quarter last year, the company earned $0.98 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. research analysts forecast that STERIS will post 4.13 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th were paid a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend was Tuesday, February 27th. This is a boost from STERIS’s previous quarterly dividend of $0.21. STERIS’s dividend payout ratio (DPR) is presently 32.98%.
A number of research firms have issued reports on STE. Zacks Investment Research cut shares of STERIS from a “buy” rating to a “hold” rating in a report on Friday. KeyCorp restated a “buy” rating and set a $103.00 price target on shares of STERIS in a report on Thursday, February 8th. Northcoast Research set a $102.00 price target on shares of STERIS and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, Raymond James Financial restated a “market perform” rating and set a $100.00 price target on shares of STERIS in a report on Wednesday, January 3rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. STERIS has a consensus rating of “Buy” and an average price target of $85.00.
COPYRIGHT VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/steris-plc-ste-holdings-raised-by-paloma-partners-management-co.html.
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.